Pathobiology and management of laboratory rodents administered CDC category A agents

Comparative Medicine

Volumn 57, Issue 1, 2007, Pages 18-32

  He, Yongqun ^a   Rush, Howard G ^a   Liepman, Rachel S ^a   Xiang, Zuoshuang ^a   Colby, Lesley A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX; BIOSAFETY; BOTULISM; CLINICAL PROTOCOL; DISEASE MODEL; DISEASE TRANSMISSION; DISINFECTION; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL HOST; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; HAMSTER; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTERNET; LABORATORY PERSONNEL; MEDICAL RESEARCH; NONHUMAN; OCCUPATIONAL HAZARD; PLAGUE; REVIEW; RODENT; SMALLPOX; TULAREMIA; VIRUS HEMORRHAGIC FEVER;

ANIMALS; ANTHRAX; BOTULISM; DATABASES, FACTUAL; HEMORRHAGIC FEVERS, VIRAL; HUMANS; INFECTION CONTROL; LABORATORY ANIMAL SCIENCE; MODELS, ANIMAL; PLAGUE; RISK MANAGEMENT; RODENTIA; SMALLPOX; SPECIES SPECIFICITY; SPECIMEN HANDLING; TULAREMIA;

EID: 33847311372     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Anderson GW Jr, Heath DG, Bolt CR, Welkos SL, Friedlander AM. 1998. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58:793-799.
2. Anthony LS, Skamene E, Kongshavn PA. 1988. Influence of genetic background on host resistance to experimental murine tularemia. Infect Immun 56:2089-2093.
3. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. 2001. Botulinum toxin as a biological weapon: medical and public health management. J Am Med Assoc 285:1059-1070.
4. Bausch DG, Demby AH, Coulibaly M, Kanu J, Goba A, Bah A, Conde N, Wurtzel HL, Cavallaro KF, Lloyd E, Baldet FB, Cisse SD, Fofona D, Savane IK, Tolno RT, Mahy B, Wagoner KD, Ksiazek TG, Peters CJ, Rollin PE. 2001. Lassa fever in Guinea: 1. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 1:269-281.
5. Beatty ME, Ashford DA, Griffin PM, Tauxe RV, Sobel J. 2003. Gastrointestinal anthrax: review of the literature. Arch Intern Med 163:2527-2531.
6. Benning N, Hassett DE. 2004. Vaccinia virus infection during murine pregnancy: a new pathogenesis model for vaccinia fetalis. J Virol 78:3133-3139.
7. Block SS. 2001. Disinfection, sterilization, and preservation, 5th ed. Philadelphia: Lea and Febiger.
8. Boyden ED, Dietrich WF. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38:240-244.
9. Boyle JJ, Haff RF, Stewart RC. 1966. Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrobial Agents Chemother (Bethesda) 6:536-539.
10. Bray M. 2003. Defense against filoviruses used as biological weapons. Antiviral Res 57:53-60.
11. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. 1999. A mouse model for evaluation of prophylaxis and therapy of ebola hemorrhagic fever. J Infect Dis. 179(Suppl 1):S248-S258.
12. Bray M, Hatfill S, Hensley L, Huggins JW. 2001. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of ebola Zaire virus. J Comp Pathol 125:243-253.
13. Briody BA. 1959. Response of mice to ectromelia and vaccinia viruses. Bacteriol Rev 23:61-95.
14. Buer J, Balling R. 2003. Mice, microbes and models of infection. Nat Rev Genet 4:195-205.
15. Butcher W, Ulaeto D. 2005. Contact inactivation of orthopoxviruses by household disinfectants. J Appl Microbiol 99:279-284.
16. Casillas AM, Nyamathi AM, Sosa A, Wilder CL, Sands H. 2003. A current review of ebola virus: pathogenesis, clinical presentation, and diagnostic assessment. Biol Res Nurs 4:268-275.
17. Centers for Disease Control and Prevention. 1988. Management of patients with suspected viral hemorrhagic fever. Morb Mortal Wkly Rep 37(Suppl 3):1-16.
18. Centers for Disease Control and Prevention. 1990. Update: filovirus infection in animal handlers. Morb Mortal Wkly Rep 39:221.
19. Centers for Disease Control and Prevention. 1995. Update: management of patients with suspected viral hemorrhagic fever-United States. Morb Mortal Wkly Rep 44:475-479.
20. Centers for Disease Control and Prevention. 1996. Ebola-Reston virus infection among quarantined nonhuman primates-Texas, 1996. Morb Mortal Wkly Rep 45:314-316.
21. Centers for Disease Control and Prevention. 1996. Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 45:1-15.
22. Centers for Disease Control and Prevention. 1998. Botulism in the United States, 1899-1996 handbook for epidemiologists, clinicians, and laboratory workers. Atlanta: Centers for Disease Control and Prevention.
23. Centers for Disease Control and Prevention. 2006. Lassa fever fact sheet [Internet]. Atlanta: Centers for Disease Control and Prevention [updated 2004 Dec; cited 14 June 2006]. Available from: http://www.cdc.gov/ncidod/dvrd/ spb/mnpages/dispages/lassaf.htm.
24. Centers for Disease Control and Prevention. 2006. Vaccinia (small-pox) vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001 [Internet]. Atlanta: Centers for Disease Control and Prevention [updated 2001 Jun; cited 14 June 2006]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5010a1.htm.
25. Chappard D, Chennebault A, Moreau M, Legrand E, Audran M, Basle MF. 2001. Texture analysis of X-ray radiographs is a more reliable descriptor of bone loss than mineral content in a rat model of localized disuse induced by the Clostridium botulinum toxin. Bone 28:72-79.
26. Chen W, Shen H, Webb A, KuoLee R, Conlan JW. 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21:3690-3700.
27. Childs JE, Mills JN, Glass GE. 1995. Rodent-borne hemorrhagic fever viruses: a special risk for mammalogists? J Mammal 76:664-680.
28. Conlan JW, Chen W, Shen H, Webb A, KuoLee R. 2003. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 34:239-248.
29. Conlan JW, KuoLee R, Shen H, Webb A. 2002. Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog 32:127-134.
30. Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, Jahrling PB. 1999. Pathogenesis of experimental ebola virus infection in guinea pigs. J Infect Dis 179 Suppl 1:S203-S217.
31. Cronquist SD. 2004. Tularemia: the disease and the weapon. Dermatol Clin 22:313-320, vi-vii.
32. Cui X, Li Y, Moayeri M, Choi GH, Subramanian GM, Li X, Haley M, Fitz Y, Feng J, Banks SM, Leppla SH, Eichacker PQ. 2005. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis 191:422-434.
33. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. 2001. Tularemia as a biological weapon: medical and public health management. J Am Med Assoc 285:2763-2773.
34. Dezfulian M, Bartlett JG. 1985. Kinetics of growth and toxigenicity of Clostridium botulinum in experimental wound botulism. Infect Immun 49:452-454.
35. Dolimbek GS, Dolimbek BZ, Aoki KR, Atassi MZ. 2005. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest 34:119-142.
36. Druilhe P, Hagan P, Rook GA. 2002. The importance of models of infection in the study of disease resistance. Trends Microbiol 10: S38-S46.
37. Duong S, Chiaraviglio L, Kirby JE. 2006. Histopathology in a murine model of anthrax. Int J Exp Pathol 87:131-137.
38. Durham PL, Cady R, Cady R. 2004. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35-42; discussion 42-43.
39. Egan C, Kelly CD, Rush-Wilson K, Davis SW, Samsonoff WA, Pfeiffer H, Miller J, Taylor J, Cirino NM. 2004. Laboratory-confirmed transmission of vaccinia virus infection through sexual contact with a military vaccinee. J Clin Microbiol 42:5409-5411.
40. Elkins KL, Cowley SC, Bosio CM. 2003. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect 5:135-142.
41. Ellis J, Oyston PC, Green M, Titball RW. 2002. Tularemia. Clin Microbiol Rev 15:631-646.
42. Emergent BioSolutions. BioThrax portfolio [cited 07 January 2007]. Available at http://www.emergentbiosolutions.com/html/biothrax.aspx.
43. Emond RT, Evans B, Bowen ET, Lloyd G. 1977. A case of ebola virus infection. Br Med J 2:541-544.
44. Feldman SH. 2003. Components of gene therapy experimentation that contribute to relative risk. Comp Med 53:147-158.
45. Feldmann H, Jones SM, Schnittler HJ, Geisbert T. 2005. Therapy and prophylaxis of Ebola virus infections. Curr Opin Investig Drugs 6:823-830.
46. Fellows PF, Linscott MK, Little SF, Gibbs P, Ivins BE. 2002. Anthrax vaccine efficacy in golden Syrian hamsters. Vaccine 20:1421-1424.
47. Firoved AM, Miller GF, Moayeri M, Kakkar R, Shen Y, Wiggins JF, McNally EM, Tang WJ, Leppla SH. 2005. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol 167:1309-1320.
48. Fisher-Hoch S. 1987. Pathophysiology of shock and haemorrhage in viral haemorrhagic fevers. Southeast Asian J Trop Med Public Health 18:390-391.
49. Food and Drug Administration. 2006. Package insert, Dryvax (smallpox vaccine, dried, calf lymph type), Wyeth Laboratories [Internet]. Rockville (MD): US Food and Drug Administration [updated 2002 Nov; cited 14 June 2006]. Available from: http://www.fda.gov/cber/label/smalwye102502LB.htm.
50. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. 1991. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun 59:2922-2928.
51. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. 1997. Clinical recognition and management of patients exposed to biological warfare agents. J Am Med Assoc 278:399-411.
52. Frasier D, Talka J. 2005. Facility design considerations for select agent animal research. ILAR J 46:23-33.
53. Friedman RM, Barons, Buckler CE, Steinmuller RI. 1962. The role of antibody, delayed hypersensitivity, and interferon production in recovery of guinea pigs from primary infection with vaccinia virus. J Exp Med 116:347-356.
54. Gaertner DJ, Batchelder M, Herbst LH, Kaufman HL. 2003. Administration of vaccinia virus to mice may cause contact or bedding sentinel mice to test positive for orthopoxvirus antibodies: case report and follow-up investigation. Comp Med 53:85-88.
55. Gat O, Mendelson I, Chitlaru T, Ariel N, Altboum Z, Levy H, Weiss S, Grosfeld H, Cohen S, Shafferman A. 2005. The solute-binding component of a putative Mn(II) ABC transporter (MntA) is a novel Bacillus anthracis virulence determinant. Mol Microbiol 58:533-551.
56. Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, Davis KJ, Jaax NK. 2001. Pathogenesis of experimental ebola Zaire virus infection in BALB/c mice. J Comp Pathol 125:233-242.
57. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE. 2001. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal ebola virus infection without complete inhibition of viral replication. J Virol 75:4649-4654.
58. Hanlon CA, Niezgoda M, Shankar V, Niu HS, Koprowski H, Rupprecht CE. 1997. A recombinant vaccinia-rabies virus in the immunocompromised host: oral innocuity, progressive parenteral infection, and therapeutics. Vaccine 15:140-148.
59. Hanna PC, Ireland JA. 1999. Understanding Bacillus anthracis pathogenesis. Trends Microbiol 7:180-182.
60. Hirsh DC, Biberstrein EL. 2004. Bacillus. In: Hirsh DC, MacLachlan NJ, Walker RL, editors. Veterinary microbiology, 2nd ed. Ames (IA): Blackwell Publishing. p 170-174.
61. Hirsh DC, Biberstrein EL. 2004. Clostridium. In: Hirsh DC, MacLachlan NJ, Walker RL, editors. Veterinary microbiology, 2nd ed. Ames (IA): Blackwell Publishing. p 198-214.
62. Holt RK, Walker BK, Ruff AJ. 2002. Horizontal transmission of recombinant vaccinia virus in strain 13 guinea pigs. Contemp Top Lab Anim Sci 41:57-60.
63. Huang W, Foster JA, Rogachefsky AS. 2000. Pharmacology of botulinum toxin. J Am Acad Dermatol 43:249-259.
64. Ignatyev G, Steinkasserer A, Streltsova M, Atrasheuskaya A, Agafonov A, Lubitz W. 2000. Experimental study on the possibility of treatment of some hemorrhagic fevers. J Biotechnol 83:67-76.
65. Infectious Diseases Society of America. 2006. Anthrax: current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis [Internet]. Alexandria (VA): Infectious Diseases Society of America [updated 2006 Nov; cited 14 June 2006]. Available from: http://www.cidrap.umn.edu/idsa/bt/anthrax/biofacts/anthraxfactsheet.html.
66. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K. 2000. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. J Am Med Assoc 283:2281-2290.
67. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. J Am Med Assoc 287:2236-2252.
68. Isaacs SN. 2004. Working safely with vaccinia virus: laboratory technique and the role of vaccinia vaccination. Methods Mol Biol 269:1-14.
69. Jaax J. 2005. Administrative issues related to infectious disease research in the age of bioterrorism. ILAR J. 46:8-14.
70. Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, Nagley D, Johnson E, Jaax G, Peters C. 1995. Transmission of ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669-1671.
71. Jahrling PB, Geisbert TW, Dalgard DW, Johnson ED, Ksiazek TG, Hall WC, Peters CJ. 1990. Preliminary report: isolation of ebola virus from monkeys imported to USA. Lancet 335:502-505.
72. Jahrling PB, Smith S, Hesse RA, Rhoderick JB. 1982. Pathogenesis of lassa virus infection in guinea pigs. Infect Immun 37:771-778.
73. James AN, Ryan JP, Parkman HP. 2003. Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol 285:G291-G297.
74. Jemski JV. 1981. Respiratory tularemia: comparison of selected routes of vaccination in Fischer 344 rats. Infect Immun 34:766-772.
75. Jones SM, Day F, Stagg AJ, Williamson ED. 2000. Protection conferred by a fully recombinant subunit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 19:358-366.
76. Jones SM, Griffin KF, Hodgson I, Williamson ED. 2003. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 21:3912-3918.
77. Kobayashi R, Kohda T, Kataoka K, Ihara H, Kozaki S, Pascual DW, Staats HF, Kiyono H, McGhee JR, Fujihashi K. 2005. A novel neurotoxoid vaccine prevents mucosal botulism. J Immunol 174:2190-2195.
78. Lassnig C, Kolb A, Strobl B, Enjuanes L, Muller M. 2005. Studying human pathogens in animal models: fine tuning the humanized mouse. Transgenic Res 14:803-806.
79. Lathem WW, Crosby SD, Miller VL, Goldman WE. 2005. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci U S A 102:17786-17791.
80. Layne C. 2000. Bioterrorism: Infection control help. J Environ Health 62:21-22.
81. Lee MS, Roos JM, McGuigan LC, Smith KA, Cormier N, Cohen LK, Roberts BE, Payne LG. 1992. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J Virol 66:2617-2630.
82. Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC. 2006. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis 12:134-137.
83. Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, Salvato MS. 2005. A live attenuated vaccine for Lassa fever made by reassortment of lassa and mopeia viruses. J Virol 79:13934-13942.
84. Lupi O, Madkan V, Tyring SK. 2006. Tropical dermatology: bacterial tropical diseases. J Am Acad Dermatol 54:559-578; quiz 578-580.
85. Mahanty S, Gupta M, Paragas J, Bray M, Ahmed R, Rollin PE. 2003. Protection from lethal infection is determined by innate immune responses in a mouse model of ebola virus infection. Virology 312:415-424.
86. McClain DJ. 1997. Smallpox, chapter 27. In: Medical aspects of chemical and biological warfare [Internet]. [cited 14 June 2006]. Available from: http://www.nbc-med.org/SiteContent/Homepage/WhatsNew/MedAspects/contents. html.
87. Meloni JC. 2003. Sams teach yourself PHP, MySQL, and Apache in 24 hours. Indianapolis: Sams Publishing.
88. Midura TF. 1996. Update: infant botulism. Clin Microbiol Rev 9:119-125.
89. Moberg LJ, Sugiyama H. 1980. The rat as an animal model for infant botulism. Infect Immun 29:819-821.
90. Montecucco C, Molgo J. 2005. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol 5:274-279.
91. Moss B. 1991. Vaccinia virus: a tool for research and vaccine development. Science 252:1662-1667.
92. Moussatche, N, Tuyama M, Kato SE, Castro AP, Njaine B, Peralta RH, Peralta JM, Damaso CR, Barroso PF. 2003. Accidental infection of laboratory worker with vaccinia virus. Emerg Infect Dis 9:724-726.
93. Nierengarten MB, Lutwick LI. 2002. Developing new tularemia vaccines. Medscape infectious diseases, vol 4. [Internet]. [cited 14 June 2006]. Available from: http://www.medscape.com/viewarticle/431539.
94. National Institutes of Health. 2006. NIH guidelines for research involving recombinant DNA molecules [Internet]. Bethesda (MD): NIH [updated 2002 April]. Available from: http://www4.od.nih.gov/oba/rac/guidelines/guidelines. html.
95. National Research Council. 1996. Guide for the care and use of laboratory animals. 7th ed. Washington (DC): National Academy Press.
96. National Research Council. 1997. Occupational health and safety in the care and use of research animals. Washington (DC): National Academy Press.
97. Openshaw PJ, Alwan WH, Cherrie AH, Record FM. 1991. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 338:459.
98. Park JB, Simpson LL. 2004. Progress toward development of an inhalation vaccine against botulinum toxin. Expert Rev Vaccines 3:477-487.
99. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. 2002. Pre- and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76:6408-6412.
100. Perry RD, Fetherston JD. 1997. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10:35-66.
101. Peters CJ, Buchmeier M, Rollin PE, Ksiazek TG. 1996. Arenaviruses. In: Fields virology. Philadelphia: Lippincott Williams and Wilkins. p 1521-1551.
102. Peterson JW, Comer J E, Noffsinger DM, Wenglikowski A, Walberg KG, Chatuev BM, Chopra AK, Stanberry LR, Kang AS, Scholz WW, Sircar J. 2006. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 74:1016-1024.
103. Pike RM. 1979. Laboratory-associated infections: incidence, fatalities, causes, and prevention. Annu Rev Microbiol 33:41-66.
104. Pomerantsev AP, Staritsin NA, Mockov Yu V, Marinin LI. 1997. Expression of cereolysine A B genes in Bacillus anthracis vaccine strain ensures protection against experimental hemolytic anthrax infection. Vaccine 15:1846-1850.
105. Public Health Agency of Canada. 2006. Vaccinia virus MSDS [Internet]. Ontario: Public Health Agency of Canada [updated 2001 Sep; cited 2006 June 14]. Available from: http://www.phac-aspc.gc.ca/msds-ftss/msds160e. html
106. Quenelle DC, Collins DJ, Kern ER. 2004. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res 63:33-40.
107. Reading PC, Smith GL. 2003. A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol 84:1973-1983.
108. Rohrbach S, Olthoff A, Laskawi R, Giefer B, Gotz W. 2001. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Rhinol Laryngol 110:1045-1050.
109. Rohrbach S, Olthoff A, Laskawi R, Gotz W. 2002. Neuronal nitric oxide synthase-immunoreactivity. A neuromodulating system independent of peripheral nasal gland denervation in guinea pig nasal mucosal tissue after treatment with botulinum toxin type A. ORL J Otorhinolaryngol Relat Spec 64:330-334.
110. Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. 2002. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 8:225-230.
111. Rutala WA, Weber DJ. 2005. Cleaning, disinfection, and sterilization in Healthcare facilities (chapter 21). Washington (DC): Advisory Committee on Immunization Practices. p 21-1-21-12.
112. Ryabchikova EI, Kolesnikova LV, Luchko SV. 1999. An analysis of features of pathogenesis in two animal models of ebola virus infection. J Infect Dis 179(Suppl 1):S199-S202.
113. Sawada-Hirai R, Jiang I, Wang F, Sun SM, Nedellec R, Ruther P, Alvarez A, Millis D, Morrow PR, Kang AS. 2004. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2:5.
114. Scheckelhoff MR, Telford SR, Hu LT. 2006. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine 24:1949-1957.
115. Sebbane F, Gardner D, Long D, Gowen BB, Hinnebusch BJ. 2005. Kinetics of disease progression and host response in a rat model of bubonic plague. Am J Pathol 166:1427-1439.
116. Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ. 2006. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc Natl Acad Sci U S A 103:5526-5530.
117. Shafazand S, Doyle R, Ruoss S, Weinacker A, Raffin TA. 1999. lnhalational anthrax: epidemiology, diagnosis, and management. Chest 116:1369-1376.
118. Shapiro DS, Schwartz DR. 2002. Exposure of laboratory workers to Francisella tularensis despite a bioterrorism procedure. J Clin Microbiol 40:2278-2281.
119. Sharma SK, Singh BR. 2004. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 43:4791-4798.
120. Shearer JD, Siemann L, Gerkovich M, House RV. 2005. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. Antimicrob Agents Chemother 49:2634-2641.
121. Sjostedt A. 2006. Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen. Microbes Infect 8:561-567.
122. Smee DF, Bailey KW, Wong MH, Wandersee MK, Sidwell RW. 2004. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J Infect Dis 190:1132-1139.
123. Stark JH, Frey SE, Blum PS, Monath TP. 2006. Lack of transmission of vaccinia virus. Emerg Infect Dis 12:698-700.
124. Stephenson EH, Larson EW, Dominik JW. 1984. Effect of environmental factors on aerosol-induced Lassa virus infection. J Med Virol 14:295-303.
125. Stroher U, West E, Bugany H, Klenk HD, Schnittler HJ, Feldmann H. 2001. Infection and activation of monocytes by Marburg and ebola viruses. J Virol 75:11025-11033.
126. Sugiyama H, Mills DC. 1978. Intraintestinal toxin in infant mice challenged intragastrically with Clostridium botulinum spores. Infect Immun 21:59-63.
127. The Jackson Laboratory. Infectious disease research and the laboratory mouse, a Jackson laboratory resource manual [cited 07 January 2007]. Available at htpp://jaxmice.jax.org/literature/manuals/ infectious_disease_manual.pdf.
128. Turnbull PC. 1991. Anthrax vaccines: past, present and future. Vaccine 9:533-539.
129. Turnbull PC. 1998. Guidelines for the surveillance and control of anthrax in human and animals, 3rd ed [Internet]. Geneva: World Health Organization [cited 14 June 2006]. Available from: http://www.who.int/csr/ resources/publications/anthrax/whoemczdi986text.pdf.
130. Twine S, Bystrom M, Chen W, Forsman M, Golovliov I, Johansson A, Kelly J, Lindgren H, Svensson K, Zingmark C, Conlan W, Sjostedt A. 2005. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun 73:8345-8352.
131. US Department of Health and Human Services, CfDCaP, and National Institutes of Health. 1999. Biosafety in microbiological and biomedical laboratories, 4th ed, vol. CDC Document #017-040-00547-41. Washington (DC): Government Printing Office.
132. Wayne Conlan J, Shen H, Kuolee R, Zhao X, Chen W. 2005. Aerosol, but not intradermal, immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an αβ T cell- and interferon γ-dependent mechanism. Vaccine 23:2477-2485.
133. Webster RG, Granoff A. 1994. Encyclopedia of virology. San Diego: Academic Press.
134. Welkos S, Pitt ML, Martinez M, Friedlander A, Vogel P, Tammariello R. 2002. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine 20:2206-2214.
135. Whipple EC, Ditto AH, Shanahan RS, Gatesman JJ, Little SF, Taylor RP, Lindorfer MA. 2006. Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Mol Immunol 44:377-388.
136. Wlodaver CG, Palumbo GJ, Waner JL. 2004. Laboratory-acquired vaccinia infection. J Clin Virol 29:167-170.
137. World Health Organization. 1997. WHO recommended guidelines for epidemic preparedness and response: Ebola Haemorrhagic Fever (EHF) [Internet]. Geneva: World Health Organization [cited 14 June 2006]. Available from: http://www.who.int/csr/resources/publications/ebola/whoemcdis977E.pdf.
138. Zhou D, Han Y, Yang R. 2006. Molecular and physiological insights into plague transmission, virulence and etiology. Microbes Infect 8:273-284.